ResMed Stock Slips to 470th Place with $208 Million Trading Volume Amid Apnimed Drug Buzz

On May 21, 2025, ResMed's trading volume was $208 million, a 41.44% decrease from the previous day, ranking 470th in the day's stock market. ResMed (RMD) fell 0.95%, marking two consecutive days of decline, with a total drop of 2.99% over the past two days.

ResMed has faced skepticism from analysts following the positive results announced by Apnimed for its investigational sleep apnea drug. Despite the buzz in the retail sector, ResMed's stock has remained relatively unchanged. RBC Capital noted that the market's reaction to Apnimed's announcement has been muted, indicating a lack of significant impact on ResMed's stock performance.